LungLife AI Future Growth
Future criteria checks 5/6
LungLife AI is forecast to grow earnings and revenue by 101% and 100.6% per annum respectively. EPS is expected to grow by 102% per annum. Return on equity is forecast to be 6.2% in 3 years.
Key information
101.0%
Earnings growth rate
102.0%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 100.6% |
| Future return on equity | 6.2% |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1 | 1 | 1 | 1 | 1 |
| 12/31/2025 | 1 | 0 | 0 | N/A | 1 |
| 12/31/2024 | 0 | -4 | -3 | -3 | 1 |
| 6/30/2024 | 0 | -4 | -4 | -4 | N/A |
| 3/31/2024 | 0 | -5 | -5 | -5 | N/A |
| 12/31/2023 | 0 | -5 | -5 | -5 | N/A |
| 9/30/2023 | 0 | -6 | -5 | -5 | N/A |
| 6/30/2023 | 0 | -6 | -5 | -5 | N/A |
| 3/31/2023 | 0 | -7 | -6 | -6 | N/A |
| 12/31/2022 | 0 | -8 | -6 | -6 | N/A |
| 9/30/2022 | 0 | -7 | -9 | -8 | N/A |
| 6/30/2022 | 0 | -7 | -11 | -9 | N/A |
| 3/31/2022 | 0 | -7 | -10 | -8 | N/A |
| 12/31/2021 | 0 | -7 | -9 | -8 | N/A |
| 9/30/2021 | 0 | -7 | -6 | -5 | N/A |
| 6/30/2021 | 0 | -7 | -3 | -3 | N/A |
| 3/31/2021 | 0 | -6 | -3 | -3 | N/A |
| 12/31/2020 | 0 | -5 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9H4 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: 9H4 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 9H4 is expected to become profitable in the next 3 years.
Revenue vs Market: 9H4's revenue (100.6% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: 9H4's revenue (100.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9H4's Return on Equity is forecast to be low in 3 years time (6.2%).